Nilotinib appears safe and affects biomarkers in Alzheimer's disease clinical trial

(Georgetown University Medical Center) A Georgetown University Medical Center clinical trial investigating the cancer drug nilotinib in people with Alzheimer's disease finds that it is safe and well-tolerated, and researchers say the drug should be tested in a larger study to further determine its safety and efficacy as a potential disease-modifying strategy.